Comparative Pharmacology
Head-to-head clinical analysis: DARANIDE versus METHAZOLAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARANIDE versus METHAZOLAMIDE.
DARANIDE vs METHAZOLAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbonic anhydrase inhibitor. Inhibits carbonic anhydrase in the proximal renal tubule, reducing bicarbonate reabsorption and causing alkaline diuresis.
Carbonic anhydrase inhibitor; reduces aqueous humor secretion by inhibiting carbonic anhydrase in ciliary processes, decreasing intraocular pressure.
50 mg orally once or twice daily; maximum 100 mg/day.
Oral: 50-100 mg two to three times daily.
None Documented
None Documented
Terminal elimination half-life: 2.5-3.5 hours (prolonged in renal impairment). Clinical context: Short half-life necessitates multiple daily dosing for sustained diuretic effect.
Clinical Note
moderateMethazolamide + Etacrynic acid
"The risk or severity of adverse effects can be increased when Methazolamide is combined with Etacrynic acid."
Clinical Note
moderateMethazolamide + Bumetanide
"The risk or severity of adverse effects can be increased when Methazolamide is combined with Bumetanide."
Clinical Note
moderateMethazolamide + Hydrochlorothiazide
"The risk or severity of adverse effects can be increased when Methazolamide is combined with Hydrochlorothiazide."
Clinical Note
moderateTerminal half-life: 14-20 hours; approximately 15 hours in adults, prolonged in renal impairment
Renal: unchanged drug (approximately 50% of absorbed dose) and metabolites. Biliary/fecal: minimal.
Renal: 70-90% as unchanged drug; minor biliary/fecal (<10%)
Category C
Category C
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor
Methazolamide + Indapamide
"The risk or severity of adverse effects can be increased when Methazolamide is combined with Indapamide."